Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 3/2013

Content (19 Articles)

Original Article

ADAM17-overexpressing breast cancer cells selectively targeted by antibody–toxin conjugates

Ahmad Trad, Hinrich P. Hansen, Mohammad Shomali, Matthias Peipp, Katja Klausz, Nina Hedemann, Kosuke Yamamoto, André Mauermann, Christine Desel, Inken Lorenzen, Hilmar Lemke, Stefan Rose-John, Joachim Grötzinger

Original article

Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms

Lixin Zhang, Anda Vlad, Christine Milcarek, Olivera J. Finn

Original article

MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients

Dana Cholujova, Jana Jakubikova, Branislav Czako, Michaela Martisova, Luba Hunakova, Jozef Duraj, Martin Mistrik, Jan Sedlak

Original article

Sinomenine hydrochloride enhancement of the inhibitory effects of anti-transferrin receptor antibody-dependent on the COX-2 pathway in human hepatoma cells

Yi Hong, Juan Yang, Xin Shen, Huifen Zhu, Xiaoxu Sun, Xue Wen, Jing Bian, Heyu Hu, Lu Yuan, Juan Tao, Ping Lei, Guanxin Shen

Original article

Up-regulation of Foxp3 participates in progression of cervical cancer

Chao Zeng, Yunhong Yao, Wei Jie, Miao Zhang, Xinrong Hu, Yi Zhao, Sen Wang, Jinbao Yin, Yulan Song

Open Access Original Article

The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study

Satwinder Kaur Singh, Bart Tummers, Ton N. Schumacher, Raquel Gomez, Kees L. M. C. Franken, Els M. Verdegaal, Karoline Laske, Cécile Gouttefangeas, Christian Ottensmeier, Marij J. P. Welters, Cedrik M. Britten, Sjoerd H. van der Burg

Original article

Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts

Andrew D. Kaiser, Jules Gadiot, Aurelie Guislain, Christian U. Blank

Original article

YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α

Ario Takeuchi, Masaki Shiota, Katsunori Tatsugami, Akira Yokomizo, Kentaro Kuroiwa, Takashi Dejima, Shingo Tanaka, Momoe Itsumi, Masatoshi Eto, Seiji Naito

Original article

Peripheral CD8+ T cell proliferation is prognostic for patients with advanced thoracic malignancies

Melanie J. McCoy, Anna K. Nowak, Robbert G. van der Most, Ian M. Dick, Richard A. Lake

Original article

In vitro and in vivo effects of an anti-mouse endoglin (CD105)–immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours

Raquel Muñoz, Yolanda Arias, José Miguel Ferreras, Pilar Jiménez, Carmen Langa, María Angeles Rojo, Manuel José Gayoso, Damián Córdoba-Díaz, Carmelo Bernabéu, Tomás Girbés

Original article

Higher numbers of T-bet+ intratumoral lymphoid cells correlate with better survival in gastric cancer

Lu-jun Chen, Xiao Zheng, Yue-ping Shen, Yi-bei Zhu, Qing Li, Junjun Chen, Rui Xia, Shu-ming Zhou, Chang-ping Wu, Xue-guang Zhang, Bin-feng Lu, Jing-ting Jiang

Original article

Expression of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in non-small cell lung cancer and its significance

Xiao-wei Zhang, Xia Qin, Crystal Y. Qin, Yu-lei Yin, Yan Chen, Hui-li Zhu

Original article

The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer

Brian M. Olson, Laura E. Johnson, Douglas G. McNeel

Original article

Palmitate-derivatized human IL-2: a potential anticancer immunotherapeutic of low systemic toxicity

Sharon H. Chou, Aditya V. Shetty, Yajun Geng, Lipeng Xu, Gnanasekar Munirathinam, Anne Pipathsouk, Isaiah Tan, Timothy Morris, Bin Wang, Aoshuang Chen, Guoxing Zheng

Original article

Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide

Sandra Coral, Giulia Parisi, Hugues J. M. G. Nicolay, Francesca Colizzi, Riccardo Danielli, Elisabetta Fratta, Alessia Covre, Pietro Taverna, Luca Sigalotti, Michele Maio

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine